dopamine d2 receptor antagonists
Summary: Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS.
Stahl S. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012;125:349-51 pubmed publisher
Wang S, Han C, Lee S, Jun T, Patkar A, Masand P, et al
. Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opin Investig Drugs. 2017;26:687-698 pubmed publisher
..However, the expected benefits of the newly developed antagonists may not be great because they offer little enhanced efficacy for negative symptoms, cognition and functional outcomes. ..
da Costa I, Cavalcanti J, de Queiroz D, de Azevedo E, do Rêgo A, Araujo Filho I, et al
. Supplementation with Herbal Extracts to Promote Behavioral and Neuroprotective Effects in Experimental Models of Parkinson's Disease: A Systematic Review. Phytother Res. 2017;31:959-970 pubmed publisher
..It is suggested that further studies need be conducted to better understand the mechanisms of action of the bioactive compounds distributed in these plants. Copyright © 2017 John Wiley & Sons, Ltd. ..
Ozkan M, Johnson N, Sehirli U, Woodhall G, Stanford I. Dopamine acting at D1-like, D2-like and ?1-adrenergic receptors differentially modulates theta and gamma oscillatory activity in primary motor cortex. PLoS ONE. 2017;12:e0181633 pubmed publisher
..These results show that DA mediates complex actions acting at dopamine D1-like and D2-like receptors, ?1 adrenergic receptors and possibly DA/?1 heteromultimeric receptors to differentially modulate theta and gamma activity in M1. ..
Leysen J, Janssen P, Megens A, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994;55 Suppl:5-12 pubmed
..Moreover, it was observed that antagonism of strong D2-receptor stimulation by apomorphine in rats was achieved at less than 50% D2 occupancy by the antipsychotics.(ABSTRACT TRUNCATED AT 250 WORDS) ..
Forray C, Buller R. Challenges and opportunities for the development of new antipsychotic drugs. Biochem Pharmacol. 2017;143:10-24 pubmed publisher
Bielefeldt K. From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis. Dig Dis Sci. 2017;62:2999-3013 pubmed publisher
..Knowing about common and uncommon, but potentially serious risks may enable patients and providers to decide on effective and safe management strategies. ..
Lungu C, Aia P, Shih L, Esper C, Factor S, Tarsy D. Tardive dyskinesia due to aripiprazole: report of 2 cases. J Clin Psychopharmacol. 2009;29:185-6 pubmed publisher
Ma G, Raivio N, SabriÃ J, Ortiz J. Agonist and antagonist effects of aripiprazole on Dâ‚‚-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone. Int J Neuropsychopharmacol. 2014;18: pubmed publisher
..Such unusual effects were not seen with the typical partial agonist preclamol and are consistent with the hypothesis that aripiprazole is a functionally selective Dâ‚‚R ligand. ..